Clinical Trials

A phase 3, multicenter, double blind, randomized, placebo-controlled study of ivosidenib in subjects ≥ 18 years of age with unresectable or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 prior systemic treatment regimen

Link : https://www.clinicaltrials.gov/ct2/show/NCT06127407
Status : RECRUITING
Population : Chondrosarcoma
Description : Ivosidenib vs. placebo
PI : A. Salawu
Centers Opened : PMH
Phase : III
IIST/Pharma : Pharma